First-in-Disease Therapy for IgA Nephropathy by Everest Medicines
Everest Medicines has recently made an announcement regarding the approval of Nefecon, the pioneering treatment for primary immunoglobulin A nephropathy (IgAN), by the Hainan Medical Products Administration for clinical use.
This approval specifically applies to Shanghai Ruijin Hospital's Hainan subsidiary.
The introduction of this early-access program in Hainan signifies the initiation of a transformative treatment era for IgA nephropathy in China.
With this approval, Everest Medicines is now able to provide patients with a targeted therapy that has the potential to fundamentally alter the progression of their disease.
With an estimated 5 million IgA nephropathy (IgAN) patients, China holds the highest prevalence of primary glomerular diseases globally. Unfortunately, there are currently no approved therapies available in the country for this condition. Although non-targeted treatments like RAS inhibitors are utilized, they do not bring about fundamental changes in the progression of the disease.
Alarmingly, up to 50% of IgAN patients experiencing disease progression face the risk of kidney failure within 10-20 years, potentially necessitating dialysis or kidney transplant procedures.
IgA nephropathy (IgAN) patients in China and other Asian countries face a significant unmet medical need. Recently, the global NefIgArd study released its topline results, which examined the impact of Nefecon compared to a placebo in patients with primary IgAN. The study successfully achieved its primary endpoint, revealing that Nefecon exhibited a highly statistically significant advantage over the placebo (p value < 0.0001) in terms of estimated glomerular filtration rate (eGFR) over a two-year period.
This timeframe included nine months of Nefecon or placebo treatment, followed by 15 months of follow-up without the drug.
Nefecon has obtained regulatory approval and is being marketed in the United States, the European Union, and the United Kingdom. This means that the treatment has been authorized for use in these regions and is already available to patients.
